FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

773881003: Antiparkinson therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726863016 Antiparkinson therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726864010 Antiparkinson therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antiparkinson therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release orodispersible tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing only selegiline in oromucosal dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing carbidopa and levodopa in oromucosal dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing only carbidopa and levodopa in oromucosal dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing istradefylline (medicinal product) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing only istradefylline (medicinal product) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing istradefylline in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing only istradefylline in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely opicapone 50 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely opicapone 25 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 25 milligram and levodopa 100 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bromocriptine (as bromocriptine mesilate) 800 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa anhydrous (as carbidopa) 12.5 milligram and levodopa 50 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rasagiline (as rasagiline tartrate) 1 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rasagiline (as rasagiline mesilate) 1 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rasagiline (as rasagiline mesilate) 500 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely biperiden hydrochloride 4 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 3.15 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 1.05 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 2.1 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 520 microgram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing piribedil in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely piribedil 50 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing piribedil (medicinal product) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Piribedil Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing only piribedil in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 88 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 180 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 350 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 700 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 520 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 1.57 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 2.62 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole (as pramipexole dihydrochloride) 1.05 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely biperiden lactate 5 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 4 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 3 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 500 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rotigotine 125 microgram/1 hour prolonged-release transdermal patch (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rotigotine 41.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide 250microgram tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide 50microgram tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 25mg/100mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Lisuride 200microgram tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 25mg/250mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 10mg/100mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide 1mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 12.5mg/50mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pramipexole 350microgram tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 25mg/100mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 2.5mg/10mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 1mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic ReQuip tablets starter pack Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic Stalevo 200mg/50mg/200mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pramipexole 2.1mg modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide 1mg tablets Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Lisuride 200microgram tablets Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Rotigotine 4mg/24hours transdermal patches Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 1mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Bromocriptine 10mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 625microgram/2.5mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 5mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide 250microgram tablets and Pergolide 50microgram tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 2mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pramipexole 3.15mg modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 2mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic Stalevo 150mg/37.5mg/200mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic Stalevo 100mg/25mg/200mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 50mg/200mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic ReQuip tablets follow on pack Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Levodopa 125mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Procyclidine 2.5mg/5ml oral solution sugar free Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Ropinirole 500microgram tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 25mg/100mg modified-release tablets Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 10mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 10mg/100mg tablets Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Levodopa 100mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Co-careldopa 50mg/200mg modified-release tablets Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Ropinirole 3mg modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pramipexole 520microgram modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Ropinirole 8mg modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Procyclidine 2.5mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Levodopa 100mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Rasagiline 2mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 500micrograms/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Rasagiline 2mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Ropinirole 12mg/5ml oral suspension Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pramipexole 2.62mg modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide 50microgram tablets Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic Stalevo 75mg/18.75mg/200mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Ropinirole 2mg modified-release tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic Stalevo 175mg/43.75mg/200mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Benzatropine 1mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl 8mg/5ml oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Generic Stalevo 125mg/31.25mg/200mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 3 of 4 End

This concept is not in any reference sets

Back to Start